Skip to main content
NASDAQ:AYLA

Ayala Pharmaceuticals Competitors

$10.00
+0.20 (+2.04 %)
(As of 05/14/2021 11:09 AM ET)
Add
Compare
Today's Range
$10.00
$10.00
50-Day Range
$9.99
$12.19
52-Week Range
$8.62
$28.68
Volume809 shs
Average Volume29,391 shs
Market Capitalization$132.41 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Ayala Pharmaceuticals (NASDAQ:AYLA) Vs. PSTX, CGEN, SLDB, OYST, APTO, and GRTS

Should you be buying AYLA stock or one of its competitors? Companies in the industry of "biological products, except diagnostic" are considered alternatives and competitors to Ayala Pharmaceuticals, including Poseida Therapeutics (PSTX), Compugen (CGEN), Solid Biosciences (SLDB), Oyster Point Pharma (OYST), Aptose Biosciences (APTO), and Gritstone bio (GRTS).

Poseida Therapeutics (NASDAQ:PSTX) and Ayala Pharmaceuticals (NASDAQ:AYLA) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, earnings and risk.

Earnings and Valuation

This table compares Poseida Therapeutics and Ayala Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Poseida TherapeuticsN/AN/AN/A($6.86)-1.25
Ayala Pharmaceuticals$2.33 million56.83$-17,790,000.00N/AN/A

Poseida Therapeutics has higher earnings, but lower revenue than Ayala Pharmaceuticals.

Profitability

This table compares Poseida Therapeutics and Ayala Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Poseida TherapeuticsN/AN/AN/A
Ayala Pharmaceuticals-850.81%-625.24%-70.31%

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Poseida Therapeutics and Ayala Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Poseida Therapeutics00303.00
Ayala Pharmaceuticals01502.83

Poseida Therapeutics presently has a consensus price target of $25.00, suggesting a potential upside of 198.69%. Ayala Pharmaceuticals has a consensus price target of $24.20, suggesting a potential upside of 142.00%. Given Poseida Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Poseida Therapeutics is more favorable than Ayala Pharmaceuticals.

Institutional & Insider Ownership

41.1% of Poseida Therapeutics shares are held by institutional investors. Comparatively, 12.8% of Ayala Pharmaceuticals shares are held by institutional investors. 19.0% of Poseida Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Poseida Therapeutics beats Ayala Pharmaceuticals on 7 of the 9 factors compared between the two stocks.

Compugen (NASDAQ:CGEN) and Ayala Pharmaceuticals (NASDAQ:AYLA) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, earnings and risk.

Earnings and Valuation

This table compares Compugen and Ayala Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Compugen$17.80 million30.90$-27,340,000.00($0.43)-18.70
Ayala Pharmaceuticals$2.33 million56.83$-17,790,000.00N/AN/A

Ayala Pharmaceuticals has lower revenue, but higher earnings than Compugen.

Profitability

This table compares Compugen and Ayala Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
CompugenN/A-26.98%-23.28%
Ayala Pharmaceuticals-850.81%-625.24%-70.31%

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Compugen and Ayala Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Compugen00403.00
Ayala Pharmaceuticals01502.83

Compugen presently has a consensus price target of $18.25, suggesting a potential upside of 125.03%. Ayala Pharmaceuticals has a consensus price target of $24.20, suggesting a potential upside of 142.00%. Given Ayala Pharmaceuticals' higher probable upside, analysts plainly believe Ayala Pharmaceuticals is more favorable than Compugen.

Institutional & Insider Ownership

63.4% of Compugen shares are held by institutional investors. Comparatively, 12.8% of Ayala Pharmaceuticals shares are held by institutional investors. 9.5% of Compugen shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Compugen beats Ayala Pharmaceuticals on 7 of the 11 factors compared between the two stocks.

Solid Biosciences (NASDAQ:SLDB) and Ayala Pharmaceuticals (NASDAQ:AYLA) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, earnings and risk.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Solid Biosciences and Ayala Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Solid Biosciences01402.80
Ayala Pharmaceuticals01502.83

Solid Biosciences presently has a consensus price target of $12.40, suggesting a potential upside of 257.35%. Ayala Pharmaceuticals has a consensus price target of $24.20, suggesting a potential upside of 142.00%. Given Solid Biosciences' higher probable upside, equities analysts plainly believe Solid Biosciences is more favorable than Ayala Pharmaceuticals.

Earnings and Valuation

This table compares Solid Biosciences and Ayala Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Solid BiosciencesN/AN/A$-117,220,000.00($2.91)-1.20
Ayala Pharmaceuticals$2.33 million56.83$-17,790,000.00N/AN/A

Ayala Pharmaceuticals has higher revenue and earnings than Solid Biosciences.

Institutional & Insider Ownership

42.7% of Solid Biosciences shares are held by institutional investors. Comparatively, 12.8% of Ayala Pharmaceuticals shares are held by institutional investors. 31.2% of Solid Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Solid Biosciences and Ayala Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Solid BiosciencesN/A-194.22%-140.40%
Ayala Pharmaceuticals-850.81%-625.24%-70.31%

Ayala Pharmaceuticals (NASDAQ:AYLA) and Oyster Point Pharma (NASDAQ:OYST) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, valuation, analyst recommendations, risk, earnings, dividends and institutional ownership.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Ayala Pharmaceuticals and Oyster Point Pharma, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Ayala Pharmaceuticals01502.83
Oyster Point Pharma00103.00

Ayala Pharmaceuticals currently has a consensus target price of $24.20, suggesting a potential upside of 142.00%. Given Ayala Pharmaceuticals' higher probable upside, analysts plainly believe Ayala Pharmaceuticals is more favorable than Oyster Point Pharma.

Earnings and Valuation

This table compares Ayala Pharmaceuticals and Oyster Point Pharma's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ayala Pharmaceuticals$2.33 million56.83$-17,790,000.00N/AN/A
Oyster Point PharmaN/AN/A$-45,710,000.00($9.97)-1.65

Ayala Pharmaceuticals has higher revenue and earnings than Oyster Point Pharma.

Institutional & Insider Ownership

12.8% of Ayala Pharmaceuticals shares are owned by institutional investors. Comparatively, 70.2% of Oyster Point Pharma shares are owned by institutional investors. 36.9% of Oyster Point Pharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Ayala Pharmaceuticals and Oyster Point Pharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Ayala Pharmaceuticals-850.81%-625.24%-70.31%
Oyster Point PharmaN/A-39.61%-37.68%

Summary

Oyster Point Pharma beats Ayala Pharmaceuticals on 6 of the 10 factors compared between the two stocks.

Ayala Pharmaceuticals (NASDAQ:AYLA) and Aptose Biosciences (NASDAQ:APTO) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, valuation, analyst recommendations, risk, earnings, dividends and institutional ownership.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Ayala Pharmaceuticals and Aptose Biosciences, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Ayala Pharmaceuticals01502.83
Aptose Biosciences00803.00

Ayala Pharmaceuticals currently has a consensus target price of $24.20, suggesting a potential upside of 142.00%. Aptose Biosciences has a consensus target price of $11.6250, suggesting a potential upside of 142.69%. Given Aptose Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Aptose Biosciences is more favorable than Ayala Pharmaceuticals.

Earnings and Valuation

This table compares Ayala Pharmaceuticals and Aptose Biosciences' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ayala Pharmaceuticals$2.33 million56.83$-17,790,000.00N/AN/A
Aptose BiosciencesN/AN/A$-26,280,000.00($0.52)-9.21

Ayala Pharmaceuticals has higher revenue and earnings than Aptose Biosciences.

Institutional & Insider Ownership

12.8% of Ayala Pharmaceuticals shares are owned by institutional investors. Comparatively, 52.2% of Aptose Biosciences shares are owned by institutional investors. 6.3% of Aptose Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Ayala Pharmaceuticals and Aptose Biosciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Ayala Pharmaceuticals-850.81%-625.24%-70.31%
Aptose BiosciencesN/A-49.53%-46.65%

Summary

Aptose Biosciences beats Ayala Pharmaceuticals on 8 of the 10 factors compared between the two stocks.

Ayala Pharmaceuticals (NASDAQ:AYLA) and Gritstone bio (NASDAQ:GRTS) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, valuation, analyst recommendations, risk, earnings, dividends and institutional ownership.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Ayala Pharmaceuticals and Gritstone bio, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Ayala Pharmaceuticals01502.83
Gritstone bio10202.33

Ayala Pharmaceuticals currently has a consensus target price of $24.20, suggesting a potential upside of 142.00%. Gritstone bio has a consensus target price of $22.3333, suggesting a potential upside of 157.59%. Given Gritstone bio's higher probable upside, analysts plainly believe Gritstone bio is more favorable than Ayala Pharmaceuticals.

Earnings and Valuation

This table compares Ayala Pharmaceuticals and Gritstone bio's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ayala Pharmaceuticals$2.33 million56.83$-17,790,000.00N/AN/A
Gritstone bio$4.36 million97.83$-94,430,000.00($2.81)-3.09

Ayala Pharmaceuticals has higher earnings, but lower revenue than Gritstone bio.

Institutional & Insider Ownership

12.8% of Ayala Pharmaceuticals shares are owned by institutional investors. Comparatively, 59.0% of Gritstone bio shares are owned by institutional investors. 38.0% of Gritstone bio shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Ayala Pharmaceuticals and Gritstone bio's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Ayala Pharmaceuticals-850.81%-625.24%-70.31%
Gritstone bio-2,962.52%-101.31%-68.78%

Summary

Gritstone bio beats Ayala Pharmaceuticals on 7 of the 11 factors compared between the two stocks.


Ayala Pharmaceuticals Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Poseida Therapeutics logo
PSTX
Poseida Therapeutics
1.6$8.59+3.3%$516.33 millionN/A-1.25Earnings Announcement
Analyst Upgrade
Compugen logo
CGEN
Compugen
1.4$8.04+7.8%$506.99 million$17.80 million-21.73Earnings Announcement
Unusual Options Activity
News Coverage
Solid Biosciences logo
SLDB
Solid Biosciences
1.8$3.49+27.2%$489.72 millionN/A-1.69Gap Down
Oyster Point Pharma logo
OYST
Oyster Point Pharma
0.9$16.50+1.5%$422.14 millionN/A-4.76
Aptose Biosciences logo
APTO
Aptose Biosciences
1.4$4.79+3.5%$410.81 millionN/A-7.48
Gritstone bio logo
GRTS
Gritstone bio
1.6$8.67+6.0%$400.96 million$4.36 million-3.03Analyst Downgrade
Gap Up
Jounce Therapeutics logo
JNCE
Jounce Therapeutics
1.6$7.59+4.7%$370.23 million$147.87 million-2.52
Codiak BioSciences logo
CDAK
Codiak BioSciences
2.0$17.87+6.8%$367.25 millionN/A0.00Gap Up
AVROBIO logo
AVRO
AVROBIO
1.9$9.58+8.2%$367.12 millionN/A-2.90Earnings Announcement
Analyst Report
Fusion Pharmaceuticals logo
FUSN
Fusion Pharmaceuticals
1.4$8.42+2.0%$357.39 millionN/A0.00Earnings Announcement
Analyst Upgrade
Analyst Revision
News Coverage
Adverum Biotechnologies logo
ADVM
Adverum Biotechnologies
1.8$3.66+1.1%$354.53 million$250,000.00-2.88Analyst Downgrade
Opthea logo
OPT
Opthea
1.5$8.03+3.5%$348.96 millionN/A0.00Gap Up
Outlook Therapeutics logo
OTLK
Outlook Therapeutics
1.3$2.07+6.3%$336.80 million$8.15 million-1.66Upcoming Earnings
Gap Up
Surface Oncology logo
SURF
Surface Oncology
1.4$7.62+3.4%$319.64 million$15.36 million-11.55
Cardiff Oncology logo
CRDF
Cardiff Oncology
2.0$8.63+1.6%$318.82 million$250,000.00-3.08Earnings Announcement
Autolus Therapeutics logo
AUTL
Autolus Therapeutics
1.2$6.06+0.2%$316.69 million$2.91 million-2.11Analyst Report
News Coverage
SQZ Biotechnologies logo
SQZ
SQZ Biotechnologies
1.7$11.97+5.4%$315.62 millionN/A0.00Earnings Announcement
Freeline Therapeutics logo
FRLN
Freeline Therapeutics
1.7$9.44+7.3%$313.73 millionN/A0.00Analyst Report
News Coverage
Gap Up
Innate Pharma logo
IPHA
Innate Pharma
1.1$3.95+3.0%$312.01 million$96.12 million-11.62Gap Down
Eiger BioPharmaceuticals logo
EIGR
Eiger BioPharmaceuticals
1.8$8.12+1.1%$272.63 millionN/A-3.34Analyst Report
Analyst Revision
Cabaletta Bio logo
CABA
Cabaletta Bio
1.6$9.39+6.5%$218.87 millionN/A-6.85
CASI Pharmaceuticals logo
CASI
CASI Pharmaceuticals
1.7$1.48+4.1%$198.51 million$4.13 million-3.29Earnings Announcement
Analyst Report
News Coverage
Gap Up
ADMA Biologics logo
ADMA
ADMA Biologics
1.6$1.71+5.3%$196.47 million$29.35 million-1.99Earnings Announcement
Genfit logo
GNFT
Genfit
1.3$4.11+1.5%$188.14 million$45.88 million-2.09
Voyager Therapeutics logo
VYGR
Voyager Therapeutics
1.5$4.50+4.7%$161.85 million$104.39 million-2.74Earnings Announcement
Analyst Report
Analyst Revision
Fennec Pharmaceuticals logo
FENC
Fennec Pharmaceuticals
1.5$6.40+3.1%$161.22 millionN/A-7.80Earnings Announcement
Applied Genetic Technologies logo
AGTC
Applied Genetic Technologies
1.5$3.81+3.7%$156.90 million$2.45 million-1.79Upcoming Earnings
News Coverage
Gap Up
Gamida Cell logo
GMDA
Gamida Cell
1.4$6.67+5.5%$152.59 millionN/A-4.66Earnings Announcement
Analyst Revision
News Coverage
PolarityTE logo
PTE
PolarityTE
1.5$0.99+25.7%$150.00 million$5.65 million-0.59Earnings Announcement
Unusual Options Activity
News Coverage
Gap Down
LogicBio Therapeutics logo
LOGC
LogicBio Therapeutics
1.3$4.75+6.7%$142.47 millionN/A-2.97Earnings Announcement
Analyst Revision
News Coverage
ERYTECH Pharma logo
ERYP
ERYTECH Pharma
0.5$6.51+7.5%$140.75 millionN/A-1.66
INmune Bio logo
INMB
INmune Bio
1.5$10.28+9.6%$138.73 millionN/A-10.60Analyst Downgrade
Gap Up
Checkmate Pharmaceuticals logo
CMPI
Checkmate Pharmaceuticals
2.0$6.47+4.6%$133.43 millionN/A0.00Earnings Announcement
Gap Up
X4 Pharmaceuticals logo
XFOR
X4 Pharmaceuticals
1.8$7.71+3.4%$129.51 millionN/A-2.41Gap Down
Axcella Health logo
AXLA
Axcella Health
1.6$3.45+3.5%$125.61 millionN/A-1.60Analyst Revision
News Coverage
Champions Oncology logo
CSBR
Champions Oncology
1.8$9.34+2.9%$121.45 million$32.12 million-71.85
Brainstorm Cell Therapeutics logo
BCLI
Brainstorm Cell Therapeutics
1.3$3.38+4.7%$116.95 millionN/A-3.22
Pluristem Therapeutics logo
PSTI
Pluristem Therapeutics
1.4$3.81+7.1%$112.36 million$20,000.000.00Upcoming Earnings
Genocea Biosciences logo
GNCA
Genocea Biosciences
1.6$2.16+4.6%$112.14 millionN/A-1.49Analyst Revision
Aziyo Biologics logo
AZYO
Aziyo Biologics
1.7$11.00+1.0%$111.36 millionN/A0.00Insider Buying
Dyadic International logo
DYAI
Dyadic International
1.3$3.83+0.3%$105.81 million$1.68 million-11.26Gap Down
Cidara Therapeutics logo
CDTX
Cidara Therapeutics
1.6$2.01+0.5%$97.55 million$20.92 million-1.16Earnings Announcement
News Coverage
Protara Therapeutics logo
TARA
Protara Therapeutics
1.8$8.99+3.4%$97.47 millionN/A0.00Analyst Upgrade
La Jolla Pharmaceutical logo
LJPC
La Jolla Pharmaceutical
1.7$3.63+3.6%$96.07 million$23.05 million-1.61Analyst Downgrade
Analyst Revision
AIM ImmunoTech logo
AIM
AIM ImmunoTech
1.7$1.99+3.0%$92.30 million$140,000.000.00
TRACON Pharmaceuticals logo
TCON
TRACON Pharmaceuticals
1.7$5.99+3.0%$90.07 million$3 million-1.93
Seneca Biopharma logo
SNCA
Seneca Biopharma
0.5$4.60+14.1%$79.56 million$10,000.000.00Upcoming Earnings
Gap Up
Allena Pharmaceuticals logo
ALNA
Allena Pharmaceuticals
1.3$1.12+1.8%$65.68 millionN/A-0.89Earnings Announcement
Analyst Downgrade
Analyst Revision
News Coverage
aTyr Pharma logo
LIFE
aTyr Pharma
1.5$3.68+1.6%$57.96 million$420,000.00-1.38Earnings Announcement
News Coverage
Brickell Biotech logo
BBI
Brickell Biotech
1.6$0.84+1.7%$56.89 million$7.92 million-0.35Earnings Announcement
News Coverage
This page was last updated on 5/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.